Neuronetics, Inc.
Close on Oct 19, 2026
- Market cap
- $139.68M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 3, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | Before market open | $41.60M | $-0.05 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 5, 2026 | Before market open | $34.50M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 10, 2026 | During market hours | $41.80M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 4, 2025 | Before market open | $37.30M | $-0.13 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | Before market open | $38.10M | $-0.15 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | Before market open | $32.00M | $-0.21 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 4, 2025 | Before market open | $22.50M | $-0.33 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | $18.50M | $-0.44 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 12, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 8, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 11, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Gross margin | full year 2026 | 48% to 50% | Raised |
| Cash flow from operations and investing | full year 2026 | -$14.50M to -$10.50M | Raised |
| Operating expensesGAAP | full year 2026 | $95.00M to $100.00M | New |
| Operating expensesnon-GAAP | full year 2026 | $91.00M to $96.00M | New |
| Total revenue | full year 2026 | $160.00M to $164.00M | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Neuronetics filed with the SEC
Neuronetics Reports Second Quarter 2026 Financial and Operating Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
presentation contains estimates and other statistical data prepared by independent parties and by Neuronetics, Inc. (“Neuronetics” or the “Company”) relating to market size and growth and other data about the industry in
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Neuronetics Appoints Nir Naor Chief Financial Officer; Announces Additional Management Changes
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Neuronetics Reports First Quarter 2026 Financial and Operating Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Forward Looking Statements This presentation contains estimates and
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Neuronetics Announces Chief Financial Officer Transition
Material agreement · Exit or restructuring costs · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
presentation contains estimates and other statistical data prepared by independent parties and by Neuronetics, Inc. (“Neuronetics” or the “Company”) relating to market size and growth and other data about the industry in
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.3 to Form 8-K
Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Neuronetics Reports Third Quarter 2025 Financial and Operating Results and Announces CEO Transition Plan
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
COMPANY PRESENTATION NASDAQ: STIM November 2025 Transforming Lives Through NeuroHealth
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Neuronetics Reports Second Quarter 2025 Financial and Operating Results
Material agreement · Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Neuronetics COMPANY PRESENTATION NASDAQ: STIM August 2025 Transforming Lives Through NeuroHealth
Material agreement · Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Neuronetics Appoints New Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Neuronetics Reports First Quarter 2025 Financial and Operating Results
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
COMPANY PRESENTATION NASDAQ: STIM May
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Neuronetics Reports Updated Fourth Quarter and Full Year 2024 Financial and Operating Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K/A
Neuronetics Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Forward Looking Statements This presentation contains estimates and
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Neuronetics Announces Launch of Underwritten Public Offering of Common Stock
Material agreement · Other events · EX-99.1 to Form 8-K
Neuronetics Announces Pricing of $18 Million Underwritten Public Offering of Common Stock
Material agreement · Other events · EX-99.2 to Form 8-K
Neuronetics Provides Business Update and Issues 2025 Guidance
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Strategic Update January 2025 Exhibit
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Neuronetics and Greenbrook TMS Announce Closing of Transaction
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Correction: Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K/A
Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
FDA-Cleared as an Adjunct Therapy for Ages 15 to 21!
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Neuronetics and Greenbrook TMS Announce Receipt of Interim Order in Respect
Regulation FD disclosure · EX-99.1 to Form 8-K
Forward Looking Statements This presentation contains estimates and
Regulation FD disclosure · EX-99.1 to Form 8-K
Neuronetics, Inc. Bill Leonard President & CEO, Greenbrook TMS
Regulation FD disclosure · EX-99.1 to Form 8-K
President & CEO, Greenbrook TMS
Regulation FD disclosure · EX-99.2 to Form 8-K
Canaccord Genuity 44th Annual Growth
Regulation FD disclosure · EX-99.1 to Form 8-K
Good day, and thank you for standing by. Welcome to the Neuronetics Second Quarter 2024 Financial and Operating Results Conference Call. [Operator
Results of operations · EX-99.1 to Form 8-K
Neuronetics Reports Record Second Quarter 2024 Financial and Operating Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Neuronetics and Greenbrook TMS Announce Definitive Agreement to Merge
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
“predict,” “may,” “will,” “could,” “would” and “should” as well as the negative of these terms and similar expressions. These statements include those relating to the
Regulation FD disclosure · EX-99.1 to Form 8-K
Neuronetics Reports Record First Quarter 2024 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Neuronetics Reports Record Fourth Quarter and Record Full Year 2023 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K